nach oben

Erschienen in:

13.02.2024 | Research

Repeated surgical resections for management of high-grade glioma and its impact on quality of life

verfasst von: Jun Min Koay, Loizos Michaelides, Diogo P. Moniz-Garcia, Alfredo Quinones-Hinojosa, Kaisorn Chaichana, Joao Paulo Almeida, Benjamin F. Gruenbaum, Wendy J. Sherman, David S. Sabsevitz

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

High-grade gliomas (HGG) are aggressive cancers, and their recurrence is inevitable, despite advances in treatment options. While repeated tumor resection has been shown to increase survival rate, its impact on quality of life is not clearly defined. To address this gap, we compared quality of life (QoL) changes in HGG patients who underwent first-time (FTR) versus repeat surgical resections (RSR) for management of recurrence.

Methods

Forty-four adults with HGG who underwent tumor resection were included in this study and classified into either the FTR group (n = 23) or the RSR group (n = 21). All patients completed comprehensive neuropsychological evaluations that included the Functional Assessment of Cancer Therapy-General (FACT-G) and Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scales, pre-operatively and at two weeks post-operatively.

Results

There was no difference between the FTR and RSR groups in any of the QoL indices (all p > .05), except for improved emotional well-being and worsened social well-being, suggesting minimal detrimental effects of repeat surgeries on QoL in comparison to first time surgery.

Conclusions

These results suggest that repeated resection is a viable strategy in certain cases for management of HGG recurrence, with similar impact on QoL as observed in patients undergoing first time surgery. These encouraging outcomes provide useful insight to guide treatment strategies and patient and clinician decision making to optimize surgical and functional outcomes.

Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2022) CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro-Oncol 24(Supplement_5):v1-v95. https://doi.org/10.1093/neuonc/noac202

Zhou X, Liao X, Zhang B, He H, Shui Y, Xu W, Jiang C, Shen L, Wei Q (2016) Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy. Mol Clin Oncol 5(2):289–294. https://doi.org/10.3892/mco.2016.936CrossRefPubMedPubMedCentral

Chaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia GL, Blakeley J, Lim M, Brem H, Quiñones-Hinojosa A (2013) Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 118(4):812–820. https://doi.org/10.3171/2012.9.JNS1277CrossRefPubMed

Hong B, Wiese B, Bremer M, Heissler HE, Heidenreich F, Krauss JK, Nakamura M (2013) Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme. Am J Clin Oncol 36(3):261–268. https://doi.org/10.1097/COC.0b013e3182467bb1CrossRefPubMed

Djamel-Eddine YC, De Witte O, Melot C, Lefranc F (2019) Recurrent glioblastomas: should we operate a second and even a third time? Interdisciplinary Neurosurgery 18:100551. https://doi.org/10.1016/j.inat.2019.100551CrossRef

Ringel F, Pape H, Sabel M, Krex D, Bock HC, Misch M, Weyerbrock A, Westermaier T, Senft C, Schucht P, Meyer B, Simon M, SN1 study group (2016) Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol 18(1):96-104.https://doi.org/10.1093/neuonc/nov145

Krajewski S, Furtak J, Zawadka-Kunikowska M, Kachelski M, Birski M, Harat M (2022) Rehabilitation outcomes for patients with motor deficits after initial and repeat brain tumor surgery. Int J Environ Res Public Health 19(17):10871. https://doi.org/10.3390/ijerph191710871CrossRefPubMedPubMedCentral

Yang K, Ellenbogen Y, Martyniuk A, Sourour M, Takroni R, Somji M, Gardiner E, Hui K, Odedra D, Larrazabal R, Algird A, Kachur E, Reddy K, Murty N, Farrokhyar F, Singh SK (2022) Reoperation in adult patients with recurrent glioblastoma: A matched cohort analysis. Neurooncol Adv 4(1):vdac115. https://doi.org/10.1093/noajnl/vdac115

Hoover JM, Nwojo M, Puffer R, Mandrekar J, Meyer FB, Parney IF (2013) Surgical outcomes in recurrent glioma: clinical article. J Neurosurg 118(6):1224–1231. https://doi.org/10.3171/2013.2.JNS121731CrossRefPubMed

10.

McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A (2009) Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 65(3):463–470. https://doi.org/10.1227/01.NEU.0000349763.42238.E9CrossRefPubMed

11.

Rahman M, Abbatematteo J, De Leo EK, Kubilis PS, Vaziri S, Bova F, Sayour E, Mitchell D, Quinones-Hinojosa A (2017) The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma. J Neurosurg 127(1):123–131. https://doi.org/10.3171/2016.7.JNS16396CrossRefPubMed

12.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRefPubMed

13.

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106CrossRefPubMedPubMedCentral

14.

Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579. https://doi.org/10.1200/JCO.1993.11.3.570CrossRefPubMed

15.

Henneghan AM, Van Dyk K, Kaufmann T, Harrison R, Gibbons C, Heijnen C, Kesler SR (2021) Measuring self-reported cancer-related cognitive impairment: recommendations from the cancer neuroscience initiative working group. J Natl Cancer Inst 113(12):1625–1633. https://doi.org/10.1093/jnci/djab027CrossRefPubMedPubMedCentral

16.

Dyk KV, Crespi CM, Petersen L, Ganz PA (2019) Identifying cancer-related cognitive impairment using the FACT-Cog perceived cognitive impairment. JNCI Cancer Spectr 4(1):pkz099. https://doi.org/10.1093/jncics/pkz099

17.

Edianto D, Yaznil MR, Chartyansari AA, Effendi IH (2019) Assessment of the quality of life for gynecologic cancer patients using functional assessment of cancer therapy-general (Fact-G) questionnaire at Haji Adam Malik Hospital. Open Access Maced J Med Sci 7(16):2569–2573. https://doi.org/10.3889/oamjms.2019.391CrossRefPubMedPubMedCentral

18.

Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young KL, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CA, Ahles TA, Morrow GR (2016) Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a Nationwide, multicenter, Prospective Longitudinal Study. J Clin Oncol 35(5):506–514. https://doi.org/10.1200/JCO.2016.68.5826CrossRefPubMedPubMedCentral

19.

King MT, Cella D, Osoba D, Stockler M, Eton D, Thompson J, Eisenstein A (2010) Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. Patient Relat Outcome Meas 1:119–126. https://doi.org/10.2147/PROM.S10621CrossRefPubMedPubMedCentral

20.

Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, Winocur G, De Ruiter MB, Castel H (2019) Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol 30(12):1925–1940. https://doi.org/10.1093/annonc/mdz410CrossRefPubMed

21.

Yost KJ, Thompson CA, Eton DT, Allmer C, Ehlers SL, Habermann TM, Shanafelt TD, Maurer MJ, Slager SL, Link BK, Cerhan JR (2013) The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leuk Lymphoma 54(2):290–297. https://doi.org/10.3109/10428194.2012.711830CrossRefPubMed

22.

Beck AT, Steer RA, Brown GK (1996) Manual for the Beck depression inventory-II. Psychological Corporation, San Antonio, Texas

23.

Beck AT, Steer RA (1993) Beck anxiety inventory. Psychological Corporation, San Antonia, Texas

24.

McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, Olivi A, Brem H, Quinoñes-Hinojosa A (2008) Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 63(4):700–708. https://doi.org/10.1227/01.NEU.0000325729.41085.73CrossRefPubMed

25.

Pertz M, Schlegel U, Thoma P (2022) Sociocognitive functioning and psychosocial burden in patients with brain tumors. Cancers 14(3):767. https://doi.org/10.3390/cancers14030767CrossRefPubMedPubMedCentral

26.

Jenkins LM, Drummond KJ, Andrewes DG (2016) Emotional and personality changes following brain tumour resection. J Clin Neurosci 29:128–213. https://doi.org/10.1016/j.jocn.2015.12.007CrossRefPubMed

27.

Cuevas H, Danesh V, Henneghan A (2022) Self-reported cognitive function in persons with nonneurological chronic diseases: a systematic review. J Aging Res 2022:5803337. https://doi.org/10.1155/2022/5803337CrossRefPubMedPubMedCentral

28.

Ramasubbu SK, Pasricha RK, Nath UK, Rawat VS, Das B (2021) Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital. Cancer Rep (Hoboken) 4(2):e1312. https://doi.org/10.1002/cnr2.1312CrossRefPubMed

Titel: Repeated surgical resections for management of high-grade glioma and its impact on quality of life
verfasst von: Jun Min Koay
Loizos Michaelides
Diogo P. Moniz-Garcia
Alfredo Quinones-Hinojosa
Kaisorn Chaichana
Joao Paulo Almeida
Benjamin F. Gruenbaum
Wendy J. Sherman
David S. Sabsevitz
Publikationsdatum: 13.02.2024
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2024
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-024-04600-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Palliative care for in-patient malignant glioma patients in Germany

Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center

Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors

Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma

Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response